pharma · Myotonic Dystrophy type 1 and type 2 (DM1/DM2) · Non-Dystrophic Myotonias (NDM)
Lupin (Europe)
Lupin Europe GmbH
Lupin Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myotonic Dystrophy type 1 and type 2 (DM1/DM2), Non-Dystrophic Myotonias (NDM). NovaPharmaNews links 4 clinical program(s
EU HQ
37 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Employees
- 37
- Programs
- 4
- Drugs
- 9
- Patents
- 0
MEX-NM-303
Approved · small molecule · Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2)
MEX-NM-303 for Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2) is a Approved program (small_molecule) at Lupin Europe GmbH with 1 ClinicalTrials.gov record(s).
Internal code MEX-NM-303
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lupin Europe GmbH
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2)
- Status
- active
- Trials
- 1